Celsion (cln)

[Telephonics]

bizjournals.com
Celsion stock up after study results
Wednesday January 3, 2:08 pm ET


Stock in biotechnology company Celsion rose as much as 13 percent after the company reported on experiments using its heat sensitive cancer treatment.
Columbia-based Celsion says scientists at Duke University used temperature-sensitive liposomes developed by Celsion in lab experiments with rodents, and found that heat, and the time at which heat was used, showed evidence of controlling the delivery of tumor killing drugs and their effectivenes

It says the results were published Wednesday in the Journal of the National Cancer Institute.

Celsion has global licensing rights to the heat activated liposome technology. It is currently in Phase I clinical trials as a potential treatment for liver cancer and recurring breast cancer.

Celsion (AMEX: CLN - News) had $4.1 million in revenue last quarter, up 29 percent. The company cut its loses in half to $990,000, largely from resumed shipments of its prostate cancer treatment, Prolieve. The catheter kit was taken off the market for several months last year because of manufacturing defects.

Published January 3, 2007 by the Washington Business Journal